跳至主要内容

Amyloid-Tau- Neurodegeneration (ATN) Profile

Labcorp is the first company to make a fully blood-based ATN Profile commercially available - giving physicians a simple, objective test for Alzheimer's disease pathology that can help shorten the time to diagnosis.

What is ATN? 

The ATN framework establishes a means for classifying biomarkers based on the biological evidence of Alzheimer’s disease that each marker provides1. These markers are divided into three categories to reflect the three primary biological changes associated with Alzheimer’s: 

  • A for amyloid plaques: Accumulations of beta-amyloid 42 proteins begin to form plaques in the brain years before initial symptom onset 
  • T for tau tangles: The beta-amyloid 42 accumulation causes misfolding of tau proteins, which tangle into knots and disrupt normal brain cell function 
  • N for neurodegeneration: Brain cell functional impairment causes the cells to die, which exacerbates the characteristic cognitive impairment symptoms observed in Alzheimer’s patients
Category

A

Beta-Amyloid 42/40 RatioAssess levels of pathologic change consistent with Alzheimer’s disease

T

Phosphorylated Tau 181 (pTau181)

N

Neurofilament Light Chain (NfL)Assess disease severity by measuring neurodegeneration

ATN Profile for neurologists

Labcorp is the first company to make a fully blood-based ATN Profile commercially available - giving physicians a simple, objective test for Alzheimer's disease pathology that can help shorten the time to diagnosis.

Shot of a young doctor analysing brain scans on a digital tablet

484400

ATN Profile

This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology.

View Full ATN Profile

505725

AB 42/40 Ratio, Plasma

Labcorp's Beta-Amyloid 42/40 Ratio test quantifies the amount of beta­ amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of disease progression. A ratio below the cutoff is consistent with the presence of amyloid 42 plaques.

View Test

483745

pTau181, Plasma

This test detects and quantifies pTau181 proteins, which provide evidence of Alzheimer's related tau pathology.

View Test

140555

Neurofilament Light Chain (NfL)

NfL, in the context of Alzheimer's disease, provides an indication of disease severity by measuring the current level of neurodegeneration.

View Test

Advancing alzheimer's testing

We are working with blood-based biomarkers, like pTau and Nfl, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.

Explore these resources to learn more about our ATN Profile

Explore ATN RESOURCES

Learn more about our ATN Profile
 

ATN Whitepaper

Our whitepaper detailing the ATN Profile background and performance

 

Alzheimer's Brochure

Discover our broad array of Alzheimer's testing options, including the new ATN Profile

Labcorp can help meet your neurology needs

Contact a Labcorp representative to learn more about how we can help meet your neurology testing needs

References 

  1. Jack, CR, et.al. (2016). A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 87(5), 539-547. 
  2.  Hviid, C. V. B., Knudsen, C. S., & Parkner, T. (2020). Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scandinavian journal of clinical and laboratory investigation, 80(4), 291-295. 
  3. Khalil, M, et.al. (2020). Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature communications, 11(1), 812.